NPJ Schizophrenia最新文献

{"title":"Author Correction: Multivariate pattern analysis of brain structure predicts functional outcome after auditory-based cognitive training interventions.","authors":"Lana Kambeitz-Ilankovic, Sophia Vinogradov, Julian Wenzel, Melissa Fisher, Shalaila S Haas, Linda Betz, Nora Penzel, Srikantan Nagarajan, Nikolaos Koutsouleris, Karuna Subramaniam","doi":"10.1038/s41537-021-00177-w","DOIUrl":"https://doi.org/10.1038/s41537-021-00177-w","url":null,"abstract":"","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":"7 1","pages":"47"},"PeriodicalIF":5.4,"publicationDate":"2021-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8476539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10430902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No association between cortical dopamine D2 receptor availability and cognition in antipsychotic-naive first-episode psychosis.","authors":"Maria Lee,&nbsp;Helena Fatouros-Bergman,&nbsp;Pontus Plavén-Sigray,&nbsp;Pauliina Ikonen Victorsson,&nbsp;Carl M Sellgren,&nbsp;Sophie Erhardt,&nbsp;Lena Flyckt,&nbsp;Lars Farde,&nbsp;Simon Cervenka","doi":"10.1038/s41537-021-00176-x","DOIUrl":"https://doi.org/10.1038/s41537-021-00176-x","url":null,"abstract":"<p><p>Cognitive impairment is an important predictor of disability in schizophrenia. Dopamine neurotransmission in cortical brain regions has been suggested to be of importance for higher-order cognitive processes. The aim of this study was to examine the relationship between extrastriatal dopamine D2-R availability and cognitive function, using positron emission tomography and the high-affinity D2-R radioligand [¹¹C]FLB 457, in an antipsychotic-naive sample of 18 first-episode psychosis patients and 16 control subjects. We observed no significant associations between D2-R binding in the dorsolateral prefrontal cortex or hippocampus (β = 0.013-0.074, partial r = -0.037-0.273, p = 0.131-0.841). Instead, using Bayesian statistics, we found moderate support for the null hypothesis of no relationship (BF_H0:H1 = 3.3-8.2). Theoretically, our findings may suggest a lack of detrimental effects of D2-R antagonist drugs on cognition in schizophrenia patients, in line with clinical observations.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":" ","pages":"46"},"PeriodicalIF":5.4,"publicationDate":"2021-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39436926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Getting a tool gives wings even in schizophrenia: underestimation of tool-related effort in a motor imagery task.","authors":"Amandine Décombe,&nbsp;Lionel Brunel,&nbsp;Vincent Murday,&nbsp;François Osiurak,&nbsp;Delphine Capdevielle,&nbsp;Stéphane Raffard","doi":"10.1038/s41537-021-00175-y","DOIUrl":"https://doi.org/10.1038/s41537-021-00175-y","url":null,"abstract":"<p><p>Humans frequently use tools to reduce action-related efforts. Interestingly, several studies have demonstrated that individuals had tool-related biases in terms of perceived effort reduction during motor imagery tasks, despite the lack of evidence of real benefits. Reduced effort allocation has been repeatedly found in schizophrenia, but it remains unknown how schizophrenia patients perceive tool-related benefits regarding effort. Twenty-four schizophrenia patients and twenty-four nonclinical participants were instructed to move the same quantities of objects with their hands or with a tool in both real and imagined situations. Imagined and real movement durations were recorded. Similarly to nonclinical participants, patients overestimated tool-related benefits and underestimated tool-related effort in terms of time when they mentally simulated a task requiring the use of a tool. No association between movement durations and psychotic symptoms was found. Our results open new perspectives on the issue of effort in schizophrenia.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":" ","pages":"45"},"PeriodicalIF":5.4,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443579/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39422225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in cortical gene expression in the muscarinic M1 receptor knockout mouse: potential relevance to schizophrenia, Alzheimer's disease and cognition.","authors":"Brian Dean,&nbsp;Elizabeth Scarr","doi":"10.1038/s41537-021-00174-z","DOIUrl":"https://doi.org/10.1038/s41537-021-00174-z","url":null,"abstract":"<p><p>Postmortem and neuroimaging studies show low levels of cortical muscarinic M1 receptors (CHRM1) in patients with schizophrenia which is significant because CHRM signalling has been shown to change levels of gene expression and cortical gene expression is altered in schizophrenia. We decided to identify CHRM1-mediated changes in cortical gene expression by measuring levels of RNA in the cortex of the Chrm1^-/- mouse (n = 10), where there would be no signalling by that receptor, and in wild type mouse (n = 10) using the Affymetrix Mouse Exon 1.0 ST Array. We detected RNA for 15,501 annotated genes and noncoding RNA of which 1,467 RNAs were higher and 229 RNAs lower in the cortex of the Chrm1^-^/- mouse. Pathways and proteins affected by the changes in cortical gene expression in the Chrm1^-/- are linked to the molecular pathology of schizophrenia. Our human cortical gene expression data showed 47 genes had altered expression in Chrm1^-/- mouse and the frontal pole from patients with schizophrenia with the change in expression of 44 genes being in opposite directions. In addition, genes with altered levels of expression in the Chrm1^-^/- mouse have been shown to affect amyloid precursor protein processing which is associated with the pathophysiology of Alzheimer's disease, and 69 genes with altered expression in the Chrm1^-^/- mouse are risk genes associated with human cognitive ability. Our findings argue CHRM1-mediated changes in gene expression are relevant to the pathophysiologies of schizophrenia and Alzheimer's disease and the maintenance of cognitive ability in humans.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":" ","pages":"44"},"PeriodicalIF":5.4,"publicationDate":"2021-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39415996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotics for negative and positive symptoms of schizophrenia: dose-response meta-analysis of randomized controlled acute phase trials.","authors":"Michel Sabe, Nan Zhao, Alessio Crippa, Stefan Kaiser","doi":"10.1038/s41537-021-00171-2","DOIUrl":"10.1038/s41537-021-00171-2","url":null,"abstract":"<p><p>Determining the optimal antipsychotic target dose in acute phase treatment is of high clinical relevance. The effect of antipsychotics on negative symptoms should be taken into account because patients will often continue on the treatment received in the acute phase. Therefore, we conducted a formal dose-response meta-analysis of negative symptoms and positive symptoms based on a systematic review of fixed-dose randomized controlled trials (RCTs) that examined the effectiveness of antipsychotics for the acute exacerbation of schizophrenia. Forty RCTs included a total of 15,689 patients. The 95% effective doses per day for the 13 antipsychotics included and 3 long acting were mostly different for negative and positive symptoms: amisulpride (481 mg, 690.6 mg); aripiprazole (11.9 mg, 11 mg); asenapine (7.61 mg, 5.66 mg); brexpiprazole (2.1 mg, 4 mg); cariprazine (4 mg, 6.51 mg); haloperidol (6.34 mg, 7.36 mg); lurasidone (58.2 mg, 86.3 mg); olanzapine (15.5 mg, 9.52 mg); olanzapine long-acting injection (15.7 mg, 13.5 mg); paliperidone (7.2 mg, 7 mg); paliperidone long-acting injection (7.5 mg, 5.9 mg); quetiapine instant-release (264.2 mg, 316.5 mg); quetiapine extended-release (774 mg, 707.2 mg); risperidone (7.5 mg, 7.7 mg); risperidone long-acting injection (5.13 mg, 6.7 mg); sertindole (13.5 mg, 16.3 mg); and ziprasidone (71.6 mg, 152.6 mg). The shape of the dose-response curves varied across different drugs with most drugs showing a plateau at higher doses. Most dose-response curves suggested that the near-maximum effective doses could be in the lower-to-medium range of the licensed dose. Additional RCTs are necessary to establish the optimal dose.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":"7 1","pages":"43"},"PeriodicalIF":5.7,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438046/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10654340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More than a biomarker: could language be a biosocial marker of psychosis?","authors":"Lena Palaniyappan","doi":"10.1038/s41537-021-00172-1","DOIUrl":"https://doi.org/10.1038/s41537-021-00172-1","url":null,"abstract":"<p><p>Automated extraction of quantitative linguistic features has the potential to predict objectively the onset and progression of psychosis. These linguistic variables are often considered to be biomarkers, with a large emphasis placed on the pathological aberrations in the biological processes that underwrite the faculty of language in psychosis. This perspective offers a reminder that human language is primarily a social device that is biologically implemented. As such, linguistic aberrations in patients with psychosis reflect both social and biological processes affecting an individual. Failure to consider the sociolinguistic aspects of NLP measures will limit their usefulness as digital tools in clinical settings. In the context of psychosis, considering language as a biosocial marker could lead to less biased and more accessible tools for patient-specific predictions in the clinic.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":"7 1","pages":"42"},"PeriodicalIF":5.4,"publicationDate":"2021-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00172-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10649967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multivariate pattern analysis of brain structure predicts functional outcome after auditory-based cognitive training interventions.","authors":"Lana Kambeitz-Ilankovic,&nbsp;Sophia Vinogradov,&nbsp;Julian Wenzel,&nbsp;Melissa Fisher,&nbsp;Shalaila S Haas,&nbsp;Linda Betz,&nbsp;Nora Penzel,&nbsp;Srikantan Nagarajan,&nbsp;Nikolaos Koutsouleris,&nbsp;Karuna Subramaniam","doi":"10.1038/s41537-021-00165-0","DOIUrl":"https://doi.org/10.1038/s41537-021-00165-0","url":null,"abstract":"<p><p>Cognitive gains following cognitive training interventions are associated with improved functioning in people with schizophrenia (SCZ). However, considerable inter-individual variability is observed. Here, we evaluate the sensitivity of brain structural features to predict functional response to auditory-based cognitive training (ABCT) at a single-subject level. We employed whole-brain multivariate pattern analysis with support vector machine (SVM) modeling to identify gray matter (GM) patterns that predicted higher vs. lower functioning after 40 h of ABCT at the single-subject level in SCZ patients. The generalization capacity of the SVM model was evaluated by applying the original model through an out-of-sample cross-validation analysis to unseen SCZ patients from an independent validation sample who underwent 50 h of ABCT. The whole-brain GM volume-based pattern classification predicted higher vs. lower functioning at follow-up with a balanced accuracy (BAC) of 69.4% (sensitivity 72.2%, specificity 66.7%) as determined by nested cross-validation. The neuroanatomical model was generalizable to an independent cohort with a BAC of 62.1% (sensitivity 90.9%, specificity 33.3%). In particular, greater baseline GM volumes in regions within superior temporal gyrus, thalamus, anterior cingulate, and cerebellum predicted improved functioning at the single-subject level following ABCT in SCZ participants. The present findings provide a structural MRI fingerprint associated with preserved GM volumes at a single baseline timepoint, which predicted improved functioning following an ABCT intervention, and serve as a model for how to facilitate precision clinical therapies for SCZ based on imaging data, operating at the single-subject level.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":"7 1","pages":"40"},"PeriodicalIF":5.4,"publicationDate":"2021-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00165-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10646628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex differences in antipsychotic efficacy and side effects in schizophrenia spectrum disorder: results from the BeSt InTro study.","authors":"Sanne Hoekstra,&nbsp;Christoffer Bartz-Johannessen,&nbsp;Igne Sinkeviciute,&nbsp;Solveig K Reitan,&nbsp;Rune A Kroken,&nbsp;Else-Marie Løberg,&nbsp;Tor K Larsen,&nbsp;Maria Rettenbacher,&nbsp;Erik Johnsen,&nbsp;Iris E Sommer","doi":"10.1038/s41537-021-00170-3","DOIUrl":"https://doi.org/10.1038/s41537-021-00170-3","url":null,"abstract":"<p><p>Current guidelines for patients with schizophrenia spectrum disease do not take sex differences into account, which may result in inappropriate sex-specific treatment. In the BeSt InTro study, a total of 144 patients (93 men and 51 women) with a schizophrenia spectrum diagnosis and ongoing psychosis were included and randomized to amisulpride, aripiprazole, or olanzapine in flexible dose. This trial is registered with ClinicalTrials.gov (NCT01446328). Primary outcomes were sex differences in dose, dose-corrected serum levels, efficacy, and tolerability. Dosing was higher for men than for women in the aripiprazole group (p = 0.025) and, at trend level, in the olanzapine group (p = 0.056). Dose-corrected serum levels were 71.9% higher in women than in men for amisulpride (p = 0.019) and 55.8% higher in women than in men for aripiprazole (p = 0.049). In the amisulpride group, men had a faster decrease in psychotic symptoms than women (p = 0.003). Moreover, amisulpride was more effective than the other medications in men but not in women. Prolactin levels were higher in women than in men, especially for amisulpride (p < 0.001). Also, women had higher BMI increase on amisulpride compared to the two other antipsychotics (p < 0.001). We conclude that clinicians should be aware of the risks of overdosing in women, especially for amisulpride and aripiprazole. Amisulpride is highly effective in men, but in women, amisulpride showed more severe side effects and may thus not be the drug of first choice. Our study shows that sex differences should be taken into account in future studies on antipsychotics. Future research is warranted to evaluate these preliminary results.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":" ","pages":"39"},"PeriodicalIF":5.4,"publicationDate":"2021-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00170-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39323382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impaired cerebro-cerebellar white matter connectivity and its associations with cognitive function in patients with schizophrenia.","authors":"Sung Eun Kim,&nbsp;Sungcheol Jung,&nbsp;Gyhye Sung,&nbsp;Minji Bang,&nbsp;Sang-Hyuk Lee","doi":"10.1038/s41537-021-00169-w","DOIUrl":"https://doi.org/10.1038/s41537-021-00169-w","url":null,"abstract":"<p><p>Schizophrenia is a complex brain disorder of unknown etiology. Based on the notion of \"cognitive dysmetria,\" we aimed to investigate aberrations in structural white matter (WM) connectivity that links the cerebellum to cognitive dysfunction in patients with schizophrenia. A total of 112 participants (65 patients with schizophrenia and 47 healthy controls [HCs]) were enrolled and underwent diffusion tensor imaging. Between-group voxel-wise comparisons of cerebellar WM regions (superior/middle [MCP]/inferior cerebellar peduncle and pontine crossing fibers) were performed using Tract-Based Spatial Statistics. Cognitive function was assessed using the Trail Making Test Part A/B (TMT-A/B), Wisconsin Card Sorting Test (WCST), and Rey-Kim Memory Test in 46 participants with schizophrenia. WM connectivity, measured as fractional anisotropy (FA), was significantly lower in the MCP in participants with schizophrenia than in HCs. The mean FAs extracted from the significant MCP cluster were inversely correlated with poorer cognitive performance, particularly longer time to complete the TMB-B (r = 0.559, p < 0.001) and more total errors in the WCST (r = 0.442, p = 0.003). Our findings suggest that aberrant cerebro-cerebellar communication due to disrupted WM connectivity may contribute to cognitive impairments, a core characteristic of schizophrenia. Our results may expand our understanding of the neurobiology of schizophrenia based on the cerebro-cerebellar interconnectivity of the brain.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":" ","pages":"38"},"PeriodicalIF":5.4,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00169-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39307596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fingertip advanced glycation end products and psychotic symptoms among adolescents.","authors":"Mitsuhiro Miyashita,&nbsp;Syudo Yamasaki,&nbsp;Shuntaro Ando,&nbsp;Kazuhiro Suzuki,&nbsp;Kazuya Toriumi,&nbsp;Yasue Horiuchi,&nbsp;Akane Yoshikawa,&nbsp;Atsushi Imai,&nbsp;Yukihiro Nagase,&nbsp;Yasuhiro Miyano,&nbsp;Tomoko Inoue,&nbsp;Kaori Endo,&nbsp;Yuko Morimoto,&nbsp;Masaya Morita,&nbsp;Tomoki Kiyono,&nbsp;Satoshi Usami,&nbsp;Yuji Okazaki,&nbsp;Toshiaki A Furukawa,&nbsp;Mariko Hiraiwa-Hasegawa,&nbsp;Masanari Itokawa,&nbsp;Kiyoto Kasai,&nbsp;Atsushi Nishida,&nbsp;Makoto Arai","doi":"10.1038/s41537-021-00167-y","DOIUrl":"https://doi.org/10.1038/s41537-021-00167-y","url":null,"abstract":"<p><p>Case control studies have suggested that advanced glycation end products play a key role in the pathophysiology of chronic schizophrenia. However, the longitudinal association between advanced glycation end products and psychotic symptoms among drug-naïve adolescents remains unclear. This study examined whether advanced glycation end products could predict the trajectory of psychotic symptoms in drug-naive adolescents using data from prospective population-based biomarker subsample study of the Tokyo Teen Cohort. A total of 277 community-dwelling adolescents aged 13 years without antipsychotic medication were analyzed. Fingertip advanced glycation end products were measured in adolescents using noninvasive technology that can be used quickly. The trajectory of psychotic symptoms in a 12-month follow-up was assessed by experienced psychiatrists using a semi-structured interview. Of the 277 participants, 13 (4.7%) experienced persistent psychotic symptoms (psychotic symptoms at baseline and follow-up), 65 (23.5%) experienced transient psychotic symptoms (psychotic symptoms at baseline or follow-up), and 199 (71.8%) did not have psychotic symptoms. Multinomial logistic regression analysis adjusted for age and sex revealed that baseline fingertip advanced glycation end products might predict the risk of persistent psychotic symptoms (odds ratio = 1.68; 95% confidence interval, 1.05-2.69; P = 0.03). Altogether, fingertip advanced glycation end products potentially predicted the trajectory of psychotic symptoms among drug-naive adolescents, which indicated its involvement in the pathophysiology of early psychosis. Further studies are required to identify strategies to reduce adolescent advanced glycation end products, which may contribute to preventing the onset of psychosis.</p>","PeriodicalId":19328,"journal":{"name":"NPJ Schizophrenia","volume":" ","pages":"37"},"PeriodicalIF":5.4,"publicationDate":"2021-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/s41537-021-00167-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39305899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}